Association of the co-expression of SOX2 and Podoplanin in the progression of oral squamous cell carcinomas - an immunohistochemical study

Pradhan, Sonali; Guddattu, Vasudeva; Solomon, Monica Charlotte

doi:10.1590/1678-7757-2018-0348

Cited by 10 publications

(6 citation statements)

References 46 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nuclear and cytoplasmic localization of SOX2 was reported in buccal SCC 20 and ameloblastic carcinoma 21 . On the other hand, nuclear localization of SOX2 was reported in oral SCC 22 …”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical expression of SOX2 in non‐melanoma skin cancer

Abdou

Mostafa

Gafar

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Basal cell carcinoma (BCC) followed by squamous cell carcinoma (SCC) are the most common non‐melanoma skin cancer (NMSC). SOX2 is a transcription factor that acts on various phases of embryonic development and its overexpression in many tumors has been reported. Aim This work aimed to evaluate the possible role of SOX2 in pathogenesis of non‐melanoma skin cancer through its immunohistochemical assessment in BCC and SCC compared to normal skin and correlating its expression with the established prognostic factors. Methods The investigated cases were 24 BCC, 21 SCC, and 26 normal skin specimens. Results SOX2 was not expressed in normal skin, but it was upregulated in SCC (85.7%) and BCC (66.7%), with a significant difference between malignant cases and normal skin (p < 0.001). However, SOX2 expression did not differ between SCC and BCC. SOX2 expression was associated with large‐sized tumors in all malignant cases (BCC plus SCC) (p = 0.02) and in SCC (p = 0.043) alone together with its liability to be expressed in advanced stage in SCC (p = 0.063). Conclusions SOX2 was over‐expressed in cutaneous SCC and BCC without a significant difference. SOX2 may enhance progression of NMSC manifested by its association with large tumor size and advanced stage.

show abstract

“…Nuclear and cytoplasmic localization of SOX2 was reported in buccal SCC 20 and ameloblastic carcinoma 21 . On the other hand, nuclear localization of SOX2 was reported in oral SCC 22 …”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical expression of SOX2 in non‐melanoma skin cancer

Abdou

Mostafa

Gafar

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Em relação ao grau de diferenciação do tumor, o estudo de Pradhan et al (2019) apontou associação da maior expressão a maior grau histopatológico. O estudo de Liu et al Variáveis como grau de diferenciação, tamanho e estágio clínico do tumor são importantes fatores ao analisar o prognóstico do paciente com CECP.…”

Section: Discussionunclassified

Valor prognóstico do SOX2 em Carcinomas Epidermóides de Cabeça e Pescoço: Revisão sistemática

Oliveira

Costa

Sousa

et al. 2020

RSD

View full text Add to dashboard Cite

Introdução: o carcinoma epidermoide de cabeça e pescoço (CECP) é um tipo de tumor maligno bastante comum no mundo, que possui taxas de sobrevida preocupantes. Portanto, estabelecer biomarcadores, como o SOX2, que está associado a proliferação de células tronco cancerígenas (CTCs), é importante para se detectar precocemente a doença, bem como determinar o prognóstico, auxiliando no tratamento. Objetivo: analisar a atuação do SOX2 como preditor prognóstico para o CECP. Metodologia: trata-se de uma revisão sistemática da literatura realizada nas bases de dados BVS, PUBMED, Web of Science e SCOPUS, a partir da estratégia “SOX2 AND (oral squamous cell carcinoma OR head and neck squamous cell carcinoma) AND (prognosis OR aggressiveness)”. A amostra final foi composta por 19 artigos. Resultados: os dados de sobrevida demonstraram divergência entre os trabalhos: 10 estudos concluíram que a maior expressão de SOX2 associa-se a bom prognóstico, enquanto 8 concluíram o oposto. 1 artigo não apontou relação entre esses fatores. Foram analisados dados sobre ocorrência de metástases, transição epitelial mesenquimal, proliferação e invasão tumoral, resultado a radioterapia, grau, diferenciação e tamanho do tumor, sendo os apontamentos divergentes entre estudos. Conclusão: os achados clínicos apontam relações existentes entre SOX2 e o CECP, todavia, não de forma conclusiva. Assim, a literatura não respalda o uso de SOX2 como preditor prognóstico, reforçando a necessidade de elucidar os mecanismos e vias moleculares através das quais SOX2 influencia a progressão do câncer.

show abstract

“…Also, expression of SOX2 was found in 63% of OC cases. 27 Analysis of PPN thus can be an aid to prognosis and treatment of OSCC.…”

Section: + =Upregulation -=Downregulationmentioning

confidence: 99%

Molecular Biomarkers for Diagnosis of Oral Cancer: An Overview

Mojumder

Paul

Podder

2022

Int. J. Hum. Health Sci.

View full text Add to dashboard Cite

Oral cancer is one of the six leading cancers in the world and is a constant threat to the health sector in developing countries as well as developed ones. Late presentation, due to lack of awareness and invasive incisional biopsy is the crucial factor for this. Nowadays, scientists are trying to find out an easy and reliable method of early diagnosis of oral cancer and molecular biomarkers might be very helpful for that. This review was aimed to evaluate the published literature on molecular biomarkers which are related to oral cancer. For this, advanced searching was applied by specific keywords in PubMed-Medline resource database and found 12466 publications were clinical trials on humans. Then after applying all inclusion criteria, 19 articles were included finally in the review. This paper uncovered that recognition of biomarkers will be useful for the early detection of oral cancer and their prognosis after treatment. We can suggest that p53, EGFR, miR-34a, miR-143 estimation is important to decide the conceivable risk of oral malignant growth advancement in the speculated oral lesion and after the curative procedure EGFR, Podoplanin and miR-21can aid us regarding the prognosis of patient.International Journal of Human and Health Sciences Vol. 06 No. 01 January’22 Page: 11-16

show abstract

Association of the co-expression of SOX2 and Podoplanin in the progression of oral squamous cell carcinomas - an immunohistochemical study

Cited by 10 publications

References 46 publications

Immunohistochemical expression of SOX2 in non‐melanoma skin cancer

Immunohistochemical expression of SOX2 in non‐melanoma skin cancer

Valor prognóstico do SOX2 em Carcinomas Epidermóides de Cabeça e Pescoço: Revisão sistemática

Molecular Biomarkers for Diagnosis of Oral Cancer: An Overview

Contact Info

Product

Resources

About